SequelSEC

Minerva Neurosciences, Inc. NERV

Pharmaceutical Preparations · CIK 0001598646 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2024-12-31
Operating income
Unavailable
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Minerva Neurosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Minerva Neurosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-30
RevenueUnavailableUnavailableUnavailable$0$0$0$0$0$0$41.18M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailable-$21.38M-$7.52M-$8.96M-$7.51M-$7.30M-$8.09M$29.51M
Net incomeUnavailableUnavailableUnavailable-$21.31M-$9.21M-$10.59M-$8.80M-$7.32M-$8.11M$29.53M
Research & developmentUnavailableUnavailableUnavailable$18.75M$4.51M$5.52M$3.26M$3.55M$4.64M$5.77M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableshares 5.34Mshares 42.72MUnavailableUnavailableshares 41.92Mshares 40.28M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailable$-1.72$-0.25UnavailableUnavailable$-0.19$0.73
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailable$2.63M$3.00M$3.44M$4.25M$3.75M$3.45M$5.90M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Minerva Neurosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-30
Cash & equivalents$21.36M$40.91M$36.09M$60.76M$65.59M$74.21M$80.14M$25.36M$32.52M$32.25M
Total assets$37.14M$56.90M$55.09M$77.12M$97.56M$105.32M$111.83M$57.63M$65.22M$66.17M
Current assets$22.27M$42.00M$40.16M$62.20M$67.44M$75.23M$81.69M$27.44M$34.99M$35.89M
Total liabilities$62.84M$85.36M$75.11M$69.15M$69.48M$69.16M$66.46M$4.96M$7.20M$9.22M
Current liabilities$2.84M$3.34M$1.38M$2.82M$3.08M$4.44M$3.36M$3.16M$5.39M$7.40M
Total equity incl. NCI-$25.69M-$28.46M-$20.02M$7.98M$28.08M$36.17M$45.37M$52.66M$58.02M$56.94M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.61M$1.81M$969.67K$1.85M$1.20M$1.59M$1.13M$995.61K$701.58K$3.14M

Cash flow

Minerva Neurosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-30
Operating cash flowUnavailableUnavailableUnavailable-$4.83M-$8.63M-$5.92M-$5.22M-$7.16M-$9.87M-$7.59M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$3.00M$4.50M
Financing cash flowUnavailableUnavailableUnavailable$0$0$0$60.00M$0$7.14M$5.30M
Net change in cashUnavailableUnavailableUnavailable-$4.83M-$8.63M-$5.92M$54.78M-$7.16M$263.76K$2.22M
Stock-based compensationUnavailableUnavailableUnavailable$1.20M$1.11M$1.38M$1.52M$1.96M$2.06M$3.49M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$2.91K$4.37K$4.37K

Derived

Minerva Neurosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable71.7%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable8.5%
Current ratio7.85x12.57x29.15x22.07x21.88x16.93x24.32x8.68x6.49x4.85x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable-100.0%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable14.0%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NERV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.